Fundz

Who to call at Ray Therapeutics, and when

Fundz watches for the moments Ray Therapeutics starts buying, and tells you who to reach.

  • An alert the day Ray Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Ray Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Ray Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Ray Therapeutics receives $8M grant from CIRM to advance optogenetic gene therapy for Stargardt disease.

Oct 01, 2026
San DiegoBiotechnologyHealth CareScience And Engineering

Description

Ray Therapeutics, a Berkeley-based biopharmaceutical company, received an $8 million grant from the California Institute for Regenerative Medicine (CIRM). The funds will support advancement of the Phase 1/2 clinical trial and manufacturing activities for RTx-021, an optogenetic gene therapy designed to restore vision in patients with Stargardt disease. Ray Therapeutics develops bioengineered, light-sensitive proteins delivered via intravitreal injection to improve visual function in retinal degenerative diseases. The company is led by CEO Paul Bresge.

Quick answer

Ray Therapeutics receives $8M grant from CIRM to advance optogenetic gene therapy for Stargardt disease. (October 1, 2026). Ray Therapeutics is based in San Diego, California, United States.

What agreement did Ray Therapeutics announce on October 1, 2026?
Ray Therapeutics, a Berkeley-based biopharmaceutical company, received an $8 million grant from the California Institute for Regenerative Medicine (CIRM). The funds will support advancement of the Phase 1/2 clinical trial and manufacturing activities for RTx-021, an optogenetic gene therapy designed to restore vision in patients with Stargardt disease.
What does Ray Therapeutics do?
Ray Therapeutics Inc (RayTx) is a late-stage preclinical Bay Area biotechnology company pioneering the first-to-market precision optogenetic therapy for vision restoration that is highly active in ambient lighting (and...
Where is Ray Therapeutics based?
Ray Therapeutics is based in San Diego, California, United States.
Which similar companies announced agreements around the same time?
Lynk Pharmaceuticals (November 3, 2026), IgniteData (October 15, 2026), NeOnc Technologies (October 16, 2026) and Danaher (October 18, 2026) also announced agreements within 45 days of Ray Therapeutics.

Source: Fundz verified event record.

Other recent agreements in Science And Engineering and Biotechnology

Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.

Company Information

Company

Ray Therapeutics

Location

3625 Dudley Street

San Diego, California, United States

About

Ray Therapeutics Inc (RayTx) is a late-stage preclinical Bay Area biotechnology company pioneering the first-to-market precision optogenetic therapy for vision restoration that is highly active in ambient lighting (and will not require light-enhancing goggles). Our studies have shown for the first time that our proprietary ChRown optogenetic protein can restore high levels of visual acuity, contrast sensitivity and visual field. RayTx lead asset, RTx-015, is expected to address the huge unmet medical in people suffering from many forms of retinal blindness (independent of the underlying genetic cause), including those with advanced age-related macular degeneration. RayTx has partnered with a world-leading AAV gene therapy manufacturer is utilizing their proprietary commercial manufacturing process and analytics to maximally de-risk clinical development. RayTx anticipates clinical trials will begin by the end of 2023 in our initial indication, retinitis pigmentosa.

Related People

Jerrod
Senior decision-maker at this company
••••••••@••••••••

See Jerrod's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Ray Therapeutics's next move

Learn about Strategic plan

Ray Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.